Incidence, Outcomes, and Predictors of Sepsis in Hospitalized Patients with COVID-19
COVID-19 住院患者脓毒症的发生率、结果和预测因素
基本信息
- 批准号:10556324
- 负责人:
- 金额:$ 8.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-15 至 2023-08-14
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAccountingAcute Respiratory Distress SyndromeAdmission activityAdultAgeAnti-Inflammatory AgentsAwardBacteremiaBacterial InfectionsBig DataCOVID-19COVID-19 patientCOVID-19 riskCaringCenters for Disease Control and Prevention (U.S.)Cessation of lifeClinicalClinical DataCohort StudiesComplexComputer softwareConsensusCritical CareCritical IllnessDataData AnalysesData ScienceDatabasesDevelopmentDiagnosisDiscipline of NursingDiseaseElectronic Health RecordEpidemiologic MonitoringEpidemiologyEventFoundationsFunctional disorderFundingGoalsHealthHealthcare SystemsHospitalizationHospitalsHumanHypertensionImmuneImmune responseIncidenceInfectionInfectious AgentInfluenzaIntensive CareInternationalLaboratoriesLifeLungMediatingMentorsMentorshipMethodsMiningModelingModernizationMultiple Organ FailureObesityOrganOutcomePathway interactionsPatient TriagePatientsPhysiciansPhysiologicalPneumoniaPopulation trendsPreventionPrevention strategyPrognosisPublic HealthPublic PolicyRaceRecommendationReportingResearchResource AllocationResourcesRisk FactorsRisk ManagementSARS-CoV-2 infectionScientistSepsisSeptic ShockSeverity of illnessSocietiesStatistical Data InterpretationStructureTest ResultTimeTissuesTrainingUnited StatesViralVirusWorkbaseclinical diagnosiscomorbiditycoronavirus diseasedata acquisitiondemographicsevidence baseexperiencehealth care service organizationhealthcare-associated infectionsimprovedinfluenza infectioninnovationinsightmodel developmentmortalitynational surveillancenovelnovel viruspandemic diseasepathogenpatient stratificationpatient subsetspatient-clinician communicationpredictive modelingrespiratory virusrisk stratificationsevere COVID-19skills
项目摘要
SARS-CoV-2 causes a wide spectrum of illness ranging from asymptomatic infection to multiorgan
failure and death. Patients infected with SARS-CoV-2 who develop organ dysfunction technically meet the
Third International Consensus Definitions of Sepsis and Septic Shock, which define sepsis as a dysregulated
host response to infection leading to life-threatening infection. Clinicians rarely frame severe COVID-19 as
sepsis, however, despite the fact that doing so could help rapidly convey the seriousness of the condition and
invoke existing hospital structures and management pathways to optimize care for this very ill subset of
patients. At the same time, severe COVID-19 likely has unique features that differentiate it from routine
bacterial sepsis as well as from other respiratory viruses.
The overall objective of this proposal is to characterize the incidence and outcomes for COVID-19-
associated sepsis, its risk factors, and how these compare to sepsis from influenza or bacterial infections. Our
proposed project will leverage objective definitions of sepsis and organ dysfunction based on CDC’s Adult
Sepsis Event criteria, a large database with detailed electronic health record data from five hospitals, and a
research group with extensive experience using big data to conduct innovative and impactful studies on
epidemiology, diagnosis, prevention, and treatment of sepsis, pneumonia, and other healthcare-associated
infections. In Aim 1 of our proposal, we will utilize state-of-the-art methods in sepsis surveillance to provide
rigorous estimates of sepsis incidence in COVID-19 and enable evidence-based comparisons between
outcomes and risk factors for sepsis due to COVID-19 versus influenza or bacterial infections. In Aim 2, we will
incorporate patient demographics, comorbidities, vital signs, and laboratory test results available at the time of
presentation in order to predict the development of sepsis in patients with COVID-19, allowing improved risk
stratification of patients at the time of presentation and more efficient hospital resource allocation.
The proposed work will have important public health impact by informing evidence-based comparisons
of COVID-19, influenza, and bacterial sepsis to guide public policy. Characterizing the distinctive features of
sepsis in COVID-19 could also help inform better risk stratification and management strategies and generate
hypotheses into the pathophysiology of severe COVID-19.
The award will also enable the candidate, Dr. Claire Shappell, to gain essential skills in data acquisition
and analysis, predictive modeling, use of statistical analysis software, and grantsmanship, enabling her to
achieve her long term objective of becoming an independently-funded physician-scientist with expertise in
mining the increasingly abundant clinical and physiologic data available via electronic health records (EHRs) in
order to characterize population trends and identify novel opportunities for care improvement in critical illness.
SARS-CoV-2 引起多种疾病,从无症状感染到多器官感染
感染 SARS-CoV-2 的患者出现器官功能障碍,从技术上讲符合标准。
脓毒症和脓毒性休克的第三次国际共识定义,将脓毒症定义为一种失调的疾病
宿主对感染的反应导致危及生命的感染,临床医生很少将严重的 COVID-19 视为严重的感染。
然而,脓毒症,尽管这样做可以帮助迅速传达病情的严重性,并且
调用现有的医院结构和管理途径来优化对这个重病患者的护理
与此同时,重症 COVID-19 可能具有与常规患者不同的独特特征。
细菌性败血症以及其他呼吸道病毒引起的败血症。
该提案的总体目标是描述 COVID-19 的发病率和结果
相关脓毒症、其危险因素,以及这些因素与流感或细菌感染引起的脓毒症的比较。
拟议的项目将利用基于 CDC 成人的脓毒症和器官功能障碍的客观定义
脓毒症事件标准,一个包含来自五家医院的详细电子健康记录数据的大型数据库,以及
研究小组拥有丰富的经验,利用大数据进行创新和有影响力的研究
脓毒症、肺炎和其他医疗相关疾病的流行病学、诊断、预防和治疗
在我们建议的目标 1 中,我们将利用最先进的脓毒症监测方法来提供感染。
严格估计 COVID-19 中的脓毒症发病率,并能够进行基于证据的比较
在目标 2 中,我们将讨论 COVID-19 与流感或细菌感染引起的脓毒症的结果和危险因素。
纳入患者人口统计数据、合并症、生命体征和当时可用的实验室测试结果
旨在预测 COVID-19 患者败血症的发展,从而降低风险
在就诊时对患者进行分层,并更有效地分配医院资源。
拟议的工作将通过提供基于证据的比较来产生重要的公共卫生影响
COVID-19、流感和细菌性败血症的特征来指导公共政策。
COVID-19 中的脓毒症还可以帮助提供更好的风险分层和管理策略,并产生
重症 COVID-19 病理生理学的假设。
该奖项还将使候选人 Claire Shappell 博士获得数据采集方面的基本技能
和分析、预测建模、统计分析软件的使用以及资助,使她能够
实现她的长期目标,成为一名独立资助的具有专业知识的医师科学家
通过电子健康记录 (EHR) 挖掘日益丰富的临床和生理数据
为了描述人口趋势并确定改善危重疾病护理的新机会。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Claire Shappell其他文献
Claire Shappell的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Claire Shappell', 18)}}的其他基金
Antibiotic Utilization Patterns and Impact on Outcomes for Patients with Respiratory Viral Sepsis
抗生素使用模式及其对呼吸道病毒性脓毒症患者预后的影响
- 批准号:
10722745 - 财政年份:2023
- 资助金额:
$ 8.56万 - 项目类别:
Incidence, Outcomes, and Predictors of Sepsis in Hospitalized Patients with COVID-19
COVID-19 住院患者脓毒症的发生率、结果和预测因素
- 批准号:
10315279 - 财政年份:2021
- 资助金额:
$ 8.56万 - 项目类别:
Incidence, Outcomes, and Predictors of Sepsis in Hospitalized Patients with COVID-19
COVID-19 住院患者脓毒症的发生率、结果和预测因素
- 批准号:
10610089 - 财政年份:2021
- 资助金额:
$ 8.56万 - 项目类别:
相似国自然基金
套期会计有效性的研究:实证检验及影响机制
- 批准号:72302225
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
全生命周期视域的会计师事务所分所一体化治理与审计风险控制研究
- 批准号:72372064
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
兔死狐悲——会计师事务所同侪CPA死亡的审计经济后果研究
- 批准号:72302197
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
上市公司所得税会计信息公开披露的经济后果研究——基于“会计利润与所得税费用调整过程”披露的检验
- 批准号:72372025
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
环境治理目标下的公司财务、会计和审计行为研究
- 批准号:72332003
- 批准年份:2023
- 资助金额:166 万元
- 项目类别:重点项目
相似海外基金
Development of a Neutrophil Degranulation Inhibitor to Treat ARDS
开发治疗 ARDS 的中性粒细胞脱颗粒抑制剂
- 批准号:
10697442 - 财政年份:2023
- 资助金额:
$ 8.56万 - 项目类别:
Identifying patient subgroups and processes of care that cause outcome differences following ICU vs. ward triage among patients with acute respiratory failure and sepsis
确定急性呼吸衰竭和脓毒症患者在 ICU 与病房分诊后导致结局差异的患者亚组和护理流程
- 批准号:
10734357 - 财政年份:2023
- 资助金额:
$ 8.56万 - 项目类别:
Development of a Neutrophil Degranulation Inhibitor to Treat ARDS
开发治疗 ARDS 的中性粒细胞脱颗粒抑制剂
- 批准号:
10697442 - 财政年份:2023
- 资助金额:
$ 8.56万 - 项目类别:
Restoring Endothelial Function After Traumatic Injury to Reduce ARDS and Multi-Organ Dysfunction
创伤性损伤后恢复内皮功能以减少 ARDS 和多器官功能障碍
- 批准号:
10739123 - 财政年份:2023
- 资助金额:
$ 8.56万 - 项目类别:
The Intermountain West-Atlantic Center (InterACT) for the APS Phenotyping Consortium
APS 表型联盟的山间西大西洋中心 (InterACT)
- 批准号:
10649343 - 财政年份:2023
- 资助金额:
$ 8.56万 - 项目类别: